Modern approaches to the treatment of relapses and refractory forms of Langerhans cell histiocytosis. Literature review

Abstract

Despite of good outcomes in treatment of patients with newly diagnosed Langerhans cell histiocytosis (LCH), recurrences have been reported in 29.9 % of patients. There are currently no generally accepted standards for the treatment of recurrences and refractory forms of LCH. The prognosis of patients, suffering from this pathology, remains unfavorable. Current treatment approaches of recurrences and refractory forms of LCH include using of BRAF- and MEK-inhibitors and cellular treatment technologies. The article provides a literature review of current approaches to the treatment of recurrences and refractory forms of LCH and identifies the prospects for further research.